Liquid biopsy in chronic liver disease

Area of Science:

• Hepatology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• Chronic liver diseases represent a significant global health burden, impacting patient well-being and healthcare resources.
• Timely diagnosis is crucial for effective prevention, treatment, and potential cure of liver conditions.
• Conventional liver biopsy, while the gold standard, presents limitations including invasiveness and patient discomfort.

Purpose of the Study:

• To review the emerging evidence supporting the utility of liquid biopsy in the diagnosis and management of liver diseases.
• To highlight liquid biopsy as a promising tool for advancing precision medicine in hepatology.
• To explore various biomarkers detectable through liquid biopsy for liver disease assessment.

Main Methods:

• Review of current scientific literature on liquid biopsy applications in liver diseases.
• Identification and categorization of key biomarkers found in liquid biopsies.
• Analysis of the advantages of liquid biopsy over traditional methods.

Main Results:

• Liquid biopsy provides a non-invasive, repeatable, and cost-effective method for assessing liver disease.
• Identified biomarkers include circulating tumor cells, cell-free nucleic acids (DNA/RNA), and extracellular vesicles.
• These biomarkers offer molecular and cellular insights into individual patient disease states.

Conclusions:

• Liquid biopsy is a rapidly advancing field with significant potential to revolutionize liver disease diagnosis and management.
• It enables personalized treatment strategies by providing prognostic and predictive information.
• Further research into liquid biopsy biomarkers will enhance its clinical application in precision hepatology.